Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-24
2005-05-24
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S256000, C546S273100, C546S121000, C548S302700, C548S302100, C514S338000, C514S387000, C544S238000
Reexamination Certificate
active
06897225
ABSTRACT:
The present invention relates to a compound of the following formula:or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating αLβ2adhesion mediated conditions in a mammal.
REFERENCES:
patent: A-8287587 (1988-06-01), None
patent: WO 9839303 (1998-09-01), None
patent: WO 9858947 (1998-12-01), None
patent: 99 10312 (1999-03-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).*
Dyatkin, Tetrahedron Letters, vol. 38, No. 12, pp. 2065-2066 (1997).
Kelly et al., J. Immunol., vol. 163, No. 10, pp. 5173-5177 (1999).
Biano et al., J. org. Chem., vol. 65, No. 7, pp. 2179-2187 (2000).
Furth Paul
Griffith Ronald C.
Morningstar Marshall
Sircar Ila
Smith Nicholas
Berch Mark L.
Birch & Stewart Kolasch & Birch, LLP
Habte Kahsay
Tanabe Seiyaku Co. Ltd.
LandOfFree
Inhibitors of αLβ2 mediated cell adhesion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of αLβ2 mediated cell adhesion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of αLβ2 mediated cell adhesion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3416838